219 Results

People

  1. Postow
    Postow
  2. Wolchok
    Wolchok
  3. Rousseau
    Rousseau
  4. Diaz
    Diaz
  5. Iyer
    Iyer
  6. Rosenberg
    Rosenberg
  7. Shoushtari
    Shoushtari
  8. Friedman
    Friedman
  9. Hellmann
    Hellmann
  10. Voss
    Voss

Groups

  1. Department of Medicine (153)
  2. Solid Tumor Oncology Division (125)
  3. Hematologic Malignancies, Division of (58)
  4. Sloan Kettering Institute Postdocs (57)
  5. GSK Faculty (56)
  6. Melanoma and Immunotherapeutics Service (43)
  7. Surgery (40)
  8. Department of Pathology and Laboratory Medicine (35)
  9. Graduate Medical Education (30)
  10. Weinberg Fellows (30)
  1. "programmed death 1 receptor"
Formats
  1. Journal Article (153)
  2. Review (30)
  3. Editorial (25)
  4. Research Letter (5)
  5. Correspondence (3)
  6. Guidelines (2)
  7. Miscellaneous (1)
Groups
  1. Department of Medicine (153)
  2. Solid Tumor Oncology Division (125)
  3. Hematologic Malignancies, Division of (58)
  4. Sloan Kettering Institute Postdocs (57)
  5. GSK Faculty (56)
  6. Melanoma and Immunotherapeutics Service (43)

More Groups

People
  1. Jedd Wolchok (18)
  2. Michael Postow (12)
  3. Benoit Rousseau (9)
  4. Margaret Callahan (9)
  5. Taha Merghoub (9)
  6. Alexander Shoushtari (8)

More People

Years
  1. 2025 (20)
  2. 2024 (36)
  3. 2023 (20)
  4. 2022 (26)
  5. 2021 (23)
  6. 2020 (26)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (13)
  2. Clinical Cancer Research (9)
  3. Nature (8)
  4. New England Journal of Medicine (7)
  5. Annals of Oncology (5)
  6. Cancer Discovery (5)

More Publications

Publishers
  1. Nature Publishing Group (24)
  2. American Association for Cancer Research (17)
  3. Elsevier Inc. (16)
  4. Biomed Central Ltd (15)
  5. Frontiers Media S.A. (11)
  6. Elsevier Science, Inc. (10)

More Publishers

Results (219)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Local therapy for oligoprogression or consolidation in high mutational burden stage 4 colorectal cancer treated with PD-1 or PD-L1 blockade
    Journal Article

    Klemen, N. D.; Court, C. M.; Fernandes, M. C.; Walch, H. S.; Chatila, W. K.; Saadat, L. V.; Maron, S.; Crane, C.; Shia, J.; Cercek, A.; more...
    Annals of Surgical Oncology (2022)

    Fulltext@MSK | Save
  • Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS(G12D)-mutated non-small-cell lung cancer
    Journal Article

    Ricciuti, B.; Alessi, J. V.; Elkrief, A.; Wang, X.; Cortellini, A.; Li, Y. Y.; Vaz, V. R.; Gupta, H.; Pecci, F.; Barrichello, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma
    Review

    Tabernero, J.; Shen, L.; Elimova, E.; Ku, G.; Liu, T.; Shitara, K.; Lin, X.; Boyken, L.; Li, H.; Grim, J.; more...
    Future Oncology (2022)

    Fulltext@MSK | Save
  • Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer
    Journal Article

    Kim, D. W.; Kim, Y. C.; Kovari, B. P.; Chung, V.; Alese, O. B.; El-Rayes, B. F.; Li, D.; Park, W.; Kim, R. D.
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • BCG-induced tumor immunity requires tumor-intrinsic CIITA independent of MHC-II
    Journal Article

    Redelman-Sidi, G.; Binyamin, A.; Antonelli, A. C.; Catalano, W.; Bean, J.; Al-Ahmadie, H.; Jungbluth, A. A.; Glickman, M. S.
    Cancer Immunology Research (2022)

    Fulltext@MSK | Save
  • Clonal hematopoiesis and differential outcomes after immune checkpoint blockade
    Research Letter

    Hsiehchen, D.; Sfreddo, H. J.; Zhao, K.; Han, C. Y.; Morris, L. G. T.
    Cancer Cell (2022)

    Fulltext@MSK | Save
  • Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: An international multicentre observational study*
    Journal Article

    Bai, X.; Shoushtari, A. N.; Betof Warner, A.; Si, L.; Tang, B.; Cui, C.; Yang, X.; Wei, X.; Quach, H. T.; Cann, C. G.; more...
    British Journal of Dermatology (2022)

    Fulltext@MSK | Save
  • Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: An international, retrospective, cohort study
    Journal Article

    Dimitriou, F.; Namikawa, K.; Reijers, I. L. M.; Buchbinder, E. I.; Soon, J. A.; Zaremba, A.; Teterycz, P.; Mooradian, M. J.; Armstrong, E.; Nakamura, Y.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • PD-1 blockade in mismatch repair-deficient rectal cancer - The authors reply
    Correspondence

    Cercek, A.; Diaz, L. A. Jr
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection
    Journal Article

    Eroglu, Z.; Broman, K. K.; Thompson, J. F.; Nijhuis, A.; Hieken, T. J.; Kottschade, L.; Farma, J. M.; Hotz, M.; Deneve, J.; Fleming, M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save